We create innovative products that solve the unmet needs of our society.

From respiratory care to wound care, we’re engaged in creating game-changing advancements in efficacy and value that:
● beneficially impact patient healing,
● reduce the work burden of healthcare professionals and
● cut healthcare costs.

The COVID-19 pandemic is exacting a horrific human and economic toll across the globe. Harvard economist pegged its cost to the United States at $16 trillion—with $8.5 trillion for health loss and rehabilitation.

COVID has proven difficult to control due to multiple factors, including:

1. Prolonged silent incubation making effective contact tracing impractical,

2. High rate of mutation, short duration of immunity, re-infection, and

3. Extensive unvaccinated population and immense size of animal vectors and reservoir (deer, livestock, etc.) make herd immunity and viral eradication impossible.

The virus attacks endothelial cells which form the basis of our circulatory system and are ubiquitous throughout our body. Hence, severe damage to cerebrovascular, cardiopulmonary and hepatorenal systems are common, with long term consequences including loss of intellect, physical stamina and new need for oxygen supplementation or dialysis. Chronic COVID Syndrome (also known as long-haul COVID) develops in 27%-33% patients regardless of severity of infection.

When the lung tissue is assaulted by the SARS-Cov-2 virus, it becomes inflamed and can no longer perform its function of oxygen exchange properly. When cut off from the oxygen they need to maintain basic cellular functions, the remainder of the body’s vital organs succumb, and severe multi-organ damage can result. Shockingly severe hypoxia of a level previously deemed incompatible with life are routinely seen in COVID patients. Many patients requiring respiratory support end up on the ventilator, but a majority of these patients fail to come off the ventilator alive. The forced ventilation from ventilators further damages the already compromised lung tissue.

As a consequence, the new preferred go-to device for patients near respiratory failure is the HFNC (high flow nasal cannula) which costs between $5,000 to $6,500 each and requires oxygen supply at 60 LPM (86,400 liters per patient per day). As it blows oxygen at one liter per second up the nose, washout of viral particles from the airway is unavoidable. To reduce contamination risk, HFNC should be used in specially equipped negative ventilation rooms. However, the HFNC is available in limited quantifies and their increased usage has contributed to a national oxygen crisis as detailed in a John Hopkins Center for Health Security white paper.

The SentriO Oxy™, an ingenious new device which enables patients breathing spontaneously and in comfort, to receive ultra-high oxygenation comparable to that from a ventilator—but without the costly drugs, barotrauma, hemodynamic disturbances and poor odds of survival, was specifically designed to treat COVID hypoxia. Learn more by clicking here

Chronic wounds are a serious problem that affects 6.5 million Americans and costs over $50 billion a year in the United States alone. The more than 50 million annual in-patient surgical procedures as well as out-patient surgical procedures are at risk of developing SSI (surgical site infections) which cost $10 billion in uncompensated care annually. SSI is the third most costly type of healthcare-acquired infection (HAI) with an estimated cost of $20,785 per patient case. With rising costs of healthcare, the importance of affordable, infection-free healing through improved technologies becomes even more compelling. Since its founding in 2009, HealO has developed and patented a range of game-changing wound care technologies, including advanced wound therapies under the O-ACE-Sys® platform, control modules and dressings such as the ClearHeal® and BeneHeal®.